Ipsen reported healthy Q1 22 sales, with good performances in both Neuroscience and Oncology. Despite generics posing a strong threat to Somatuline, management has reiterated its 2022 guidance. On the back of a strong pipeline of internal assets, an effective external innovation strategy and important data readouts in H2 22, Ispen has become an attractive pharma / oncology bet, especially considering today’s sell-off.
27 Apr 2022
2022 begins on a healthy note
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
2022 begins on a healthy note
Ipsen reported healthy Q1 22 sales, with good performances in both Neuroscience and Oncology. Despite generics posing a strong threat to Somatuline, management has reiterated its 2022 guidance. On the back of a strong pipeline of internal assets, an effective external innovation strategy and important data readouts in H2 22, Ispen has become an attractive pharma / oncology bet, especially considering today’s sell-off.